deltatrials
Unknown PHASE2 INTERVENTIONAL 2-arm NCT03381079

Efficacy and Safety of Posterior Scleral Reinforcement on Controlling Myopia in Adults With High Myopia

Posterior Scleral Reinforcement for Adults With High Myopia

Sponsor: Beijing Tongren Hospital

Updated 6 times since 2018 Last updated: Dec 20, 2017 Started: Apr 1, 2018 Primary completion: Oct 1, 2020 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Adults and Axial Elongation, this trial is ongoing. The trial is conducted by Beijing Tongren Hospital and has accumulated 6 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotNot Yet Recruiting~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2021 – ~Jul 2024 · 41 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown StatusUnknown

  3. Feb 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Not Yet RecruitingUnknown Status

  4. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

Show 1 earlier version
  1. Jan 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beijing Tongren Hospital
Data source: Beijing Tongren Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.